STOCK TITAN

Tango Therapeutics (TNGX) grants RSUs and stock options to director

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Tango Therapeutics director Lee Sung received new equity awards consisting of restricted stock units and stock options. The filing shows a grant of 570 RSUs, each representing one share of common stock, increasing her direct common stock holdings to 22,870 shares after the award.

An additional stock option covering 3,570 shares of common stock was granted with an exercise price of $20.22 per share and an expiration date of June 5, 2036. The RSUs vest in full on the earlier of June 5, 2027 or the next annual stockholder meeting, while the option vests in 12 equal monthly installments starting July 5, 2026, in each case contingent on continued service.

Positive

  • None.

Negative

  • None.
Insider Lee Sung
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 3,570 $0.00 --
Grant/Award Common Stock 570 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 3,570 shares (Direct, null); Common Stock — 22,870 shares (Direct, null)
Footnotes (1)
  1. These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in their entirety on the earlier of: (i) June 5, 2027 and (ii) the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year, with the first vesting date on July 5, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
RSU grant size 570 RSUs Each RSU represents one share of common stock
Shares held after RSU grant 22,870 shares Director’s direct common stock holdings following award
Stock option grant size 3,570 options Options to acquire common stock granted on June 5, 2026
Option exercise price $20.22 per share Strike price for the 3,570-share option award
Option expiration June 5, 2036 Expiration date of the granted stock option
RSU vesting date Earlier of June 5, 2027 or next annual meeting RSUs vest in full at the earlier of these dates
Option vesting start July 5, 2026 First of 12 monthly vesting installments for option
restricted stock units financial
"These shares are represented by restricted stock units (the "RSUs")."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
RSUs financial
"Each RSU represents a contingent right to receive one share of Common Stock"
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
vest financial
"The RSUs will vest in their entirety on the earlier of: (i) June 5, 2027"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
exercise price financial
"conversion_or_exercise_price: "20.2200""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: "2036-06-05T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lee Sung

(Last)(First)(Middle)
C/O TANGO THERAPEUTICS, INC.,
201 BROOKLINE AVE., SUITE 901

(Street)
BOSTON MASSACHUSETTS 02215

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Tango Therapeutics, Inc. [ TNGX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/05/2026A570(1)A$022,870D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$20.2206/05/2026A3,570 (2)06/05/2036Common Stock3,570$03,570D
Explanation of Responses:
1. These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in their entirety on the earlier of: (i) June 5, 2027 and (ii) the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
2. This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year, with the first vesting date on July 5, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
Remarks:
Exhibit 24: Power of Attorney
/s/ Julie Fogarty, as attorney-in-fact06/08/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Tango Therapeutics (TNGX) director Lee Sung receive in this Form 4?

Director Lee Sung received equity-based compensation from Tango Therapeutics, including 570 restricted stock units and a stock option for 3,570 shares. These awards are part of her director compensation and are subject to future vesting conditions tied to continued service.

How many Tango Therapeutics (TNGX) shares does Lee Sung hold after these grants?

After the RSU grant, Lee Sung directly holds 22,870 shares of Tango Therapeutics common stock. This figure reflects only her reported non-derivative holdings and excludes the newly granted, unexercised stock options, which represent additional potential future ownership if exercised.

What are the terms of Lee Sung’s new stock options at Tango Therapeutics (TNGX)?

Lee Sung received a stock option for 3,570 Tango Therapeutics shares with a $20.22 exercise price and a June 5, 2036 expiration date. The option vests in 12 substantially equal monthly installments starting July 5, 2026, conditional on her continued service.

When do Lee Sung’s restricted stock units from Tango Therapeutics (TNGX) vest?

The 570 restricted stock units vest in full on the earlier of June 5, 2027 or the date of the next annual stockholder meeting. Vesting requires Lee Sung to remain in continuous service with Tango Therapeutics through the applicable vesting date specified in the award terms.

Is Lee Sung buying or selling Tango Therapeutics (TNGX) shares in this Form 4?

This Form 4 shows equity awards, not open-market buying or selling. Lee Sung is acquiring 570 RSUs and a 3,570-share stock option as compensation, both granted at no cash cost to her, subject to vesting and continued service conditions described in the disclosures.